Payment overview · 2025
General Payments
$613.24
7 reported records · 7 companies
Healthcare provider profile · identity verified
Jorge L Lacen, M.D.
Allopathic & Osteopathic Physicians|General Practice · LAKELAND, FL · NPI 1023422425
Verified facts
What the public records show
CMS Open Payments records show Jorge L Lacen, M.D. received $613.24 in general payments during 2025 across 7 reported records.
Axsome Therapeutics, Inc. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $122.10 | 19.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.34 | 15.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.05 | 15.8% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $95.25 | 15.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.36 | 14.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.46 | 13.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.68 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $613.24 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $122.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $97.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.05 | 1 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $95.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $83.46 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $28.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 378 | 253 |
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 114 |
| Losartan Potassium | Losartan Potassium | 227 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 92 |
| Gabapentin | Gabapentin | 200 | 106 |
| Lisinopril | Lisinopril | 190 | 84 |
| Metformin Hcl | Metformin Hcl | 171 | 78 |
| Azithromycin | Azithromycin | 156 | 132 |
| Famotidine | Famotidine | 145 | 76 |
| Alprazolam | Alprazolam | 139 | 61 |
| Omeprazole | Omeprazole | 134 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 54 |
| Furosemide | Furosemide | 103 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 49 |
| Glimepiride | Glimepiride | 97 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 45 |
| Simvastatin | Simvastatin | 94 | 45 |
| Meloxicam | Meloxicam | 93 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 61 |
| Eliquis | Apixaban | 82 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 46 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 41 |
| Montelukast Sodium | Montelukast Sodium | 78 | 37 |
| Ibuprofen | Ibuprofen | 67 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 53 |
| Trazodone Hcl | Trazodone Hcl | 63 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 27 |
| Tramadol Hcl | Tramadol Hcl | 61 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 36 |
| Sertraline Hcl | Sertraline Hcl | 60 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 19 |
| Carvedilol | Carvedilol | 56 | 25 |
| Ezetimibe | Ezetimibe | 56 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 24 |
| Allopurinol | Allopurinol | 52 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 26 |
| Ozempic | Semaglutide | 49 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 25 |
| Mupirocin | Mupirocin | 46 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 29 |
| Hydrocortisone | Hydrocortisone | 44 | 23 |
| Glipizide | Glipizide | 43 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 15 |
| Pregabalin | Pregabalin | 40 | 18 |
| Mounjaro | Tirzepatide | 39 | 11 |
| Potassium Chloride | Potassium Chloride | 39 | 21 |
| Ketoconazole | Ketoconazole | 38 | 18 |
| Meclizine Hcl | Meclizine Hcl | 36 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Topiramate | Topiramate | 35 | 19 |
| Clonazepam | Clonazepam | 34 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 16 |
| Metformin Hcl Er | Metformin Hcl | 33 | 15 |
| Memantine Hcl | Memantine Hcl | 32 | 16 |
| Baclofen | Baclofen | 31 | 21 |
| Clonidine Hcl | Clonidine Hcl | 31 | 16 |
| Ciclopirox | Ciclopirox | 30 | 18 |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 26 |
| Jardiance | Empagliflozin | 27 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 11 |
| Finasteride | Finasteride | 25 | 16 |
| Fluconazole | Fluconazole | 25 | 17 |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | 15 |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 18 |
| Naproxen | Naproxen | 23 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 16 |
| Metronidazole | Metronidazole | 22 | 12 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | 11 |
| Buspirone Hcl | Buspirone Hcl | 19 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Cephalexin | Cephalexin | 18 | 15 |
| Lactulose | Lactulose | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 13 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | 12 |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $613.24 · 7 records | Axsome Therapeutics, Inc. | AIRSUPRA, AREXVY, CDS - MCT/CEM Monitoring, Mavenclad, NURTEC ODT, Symbravo, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error